The training, conducted by Fluence, represents a best-in-class approach for psychotherapy that will accompany the administration of psilocybin for overeating disorders
San Diego, California--(Newsfile Corp. - August 24, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today it has completed the training of psychotherapists for its upcoming Phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for overeating disorders. The training was conducted by Fluence, which is led by researchers and psychotherapists with direct experience in psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic compounds to patients.
Tryp believes that both pharmaceutical and psychological processes will play a synergistic role to determine outcomes for TRP-8802, an oral formulation of synthetic psilocybin. Psychotherapy is an integral part of Tryp's novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming Phase 2a clinical trial for eating disorders, conducted at the University of Florida with Jennifer Miller, M.D. Following the administration of the drug, patients will also benefit from multiple integration sessions with the therapists.
Commenting on the recent psychotherapy training, Jesse Dallery, Ph.D., Director of the Behavioral Health and Technology Research Clinic and professor in the Department of Psychology at the University of Florida, said, "Establishing definitive guidelines and training for the psychotherapy portion of psychedelic therapies is essential to minimizing variability and optimizing the patient experience. I was thoroughly impressed with the rigor and scientific basis of the training provided by Fluence for our upcoming study with Tryp Therapeutics and look forward to initiating our work with patients later this year."
Tryp Therapeutics, Fluence and the University of Florida have collaborated to create a comprehensive training manual for the psychotherapy portion of Tryp's psychedelic treatment regimen that will be adapted for subsequent clinical trials in fibromyalgia and other chronic pain indications.
"We continue to be amazed by the complexity of neural networks and the array of biological and behavioral factors that influence the healthy functioning of the brain and body," said Jim Gilligan, Ph.D., President and Chief Science Officer of Tryp Therapeutics. "Our partners at the University of Florida have shown tremendous commitment to the effective administration of psychotherapy for our upcoming Phase 2a clinical trial, and Fluence continues to be an exceptional partner for the design and implementation of this important component of our therapies. The completion of this psychotherapy training marks a significant milestone for Tryp, as it remains an integral part of our novel treatment."
About Tryp Therapeutics
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The Company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and overeating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information, please visit www.tryptherapeutics.com.
Investor Inquiries:
Joe Green
Edison International
investors@tryptherapeutics.com
Media Inquiries:
Joy Willis
Tryp Therapeutics
media@tryptherapeutics.com
1-833-811-8797
Forward-Looking Information
Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans," "targets," "expects" or "does not expect," "is expected," "an opportunity exists," "is positioned," "estimates," "intends," "assumes," "anticipates" or "does not anticipate" or "believes," or variations of such words and phrases or state that certain actions, events or results "may," "could," "would," "might," "will" or "will be taken," "occur" or "be achieved." In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94046
